The best way to describe the situation Dexcom (NASDAQ: DXCM), who reported earnings this evening, finds themselves in is to think of a boxing match between two heavyweights who have fought before. Until recently Dexcom had the upper hand in these matches yet this last match their opponent, Abbott (NYSE: ABT) changed tactics. Rather than be the Abbott of old, Dexcom faced a new Abbott and rather than dominating the match got hit and bloodied a little. They were not knocked out, but they were stunned.
The reality is Abbott’s aggressive pricing posture with Libre is a problem for . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.